View ValuationImeik Technology DevelopmentLtd 将来の成長Future 基準チェック /16Imeik Technology DevelopmentLtd利益と収益がそれぞれ年間16.3%と14.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.7% 16.3%なると予測されています。主要情報16.3%収益成長率16.26%EPS成長率Biotechs 収益成長32.3%収益成長率14.6%将来の株主資本利益率18.69%アナリストカバレッジGood最終更新日20 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2026 Results on Apr 23, 2026Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Mar 19Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026, at 14:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing Chinaお知らせ • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026お知らせ • Nov 15Imeik Technology Development Co.,Ltd. Announces Directorate AppointmentsImeik Technology Development Co.,Ltd. at its EGM held on 13 November 2025 approved appointment of Jian Qing, non-independent director and Chen Zhong, non-independent director.お知らせ • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025お知らせ • Aug 21Imeik Technology Development Co.,Ltd. Proposes Interim Dividend for 2025Imeik Technology Development Co.,Ltd. proposed 2025 interim profit distribution plan. Cash dividend/10 shares (tax included): CNY 12.00000000, at the EGM to be held on September 11, 2025.お知らせ • Jul 02Imeik Technology Development Co.,Ltd. to Report First Half, 2025 Results on Aug 19, 2025Imeik Technology Development Co.,Ltd. announced that they will report first half, 2025 results on Aug 19, 2025お知らせ • Apr 22Imeik Technology Development Co.,Ltd. Approves Cash Dividend for the Year 2024Imeik Technology Development Co.,Ltd. held its Annual General Meeting of 2024 on 18 April 2025 approved the Cash dividend (tax included) of CNY 38.00000000 per 10 shares for the year 2024.お知らせ • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2025 Results on Apr 25, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025お知らせ • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing Chinaお知らせ • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 20, 2025Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 20, 2025Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥1.54 (vs CN¥1.51 in 3Q 2023)Third quarter 2024 results: EPS: CN¥1.54 (up from CN¥1.51 in 3Q 2023). Revenue: CN¥718.6m (up 1.1% from 3Q 2023). Net income: CN¥464.6m (up 2.1% from 3Q 2023). Profit margin: 65% (in line with 3Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to CN¥212, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥288 per share.Buy Or Sell Opportunity • Oct 11Now 24% undervaluedOver the last 90 days, the stock has risen 25% to CN¥212. The fair value is estimated to be CN¥278, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 63% in 2 years. Earnings are forecast to grow by 58% in the next 2 years.お知らせ • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥164, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥274 per share.Valuation Update With 7 Day Price Move • Aug 28Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥139, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥277 per share.Reported Earnings • Aug 22Second quarter 2024 earnings released: EPS: CN¥1.97 (vs CN¥1.82 in 2Q 2023)Second quarter 2024 results: EPS: CN¥1.97 (up from CN¥1.82 in 2Q 2023). Revenue: CN¥848.8m (up 2.3% from 2Q 2023). Net income: CN¥593.5m (up 8.0% from 2Q 2023). Profit margin: 70% (up from 66% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • Jun 29Imeik Technology Development Co.,Ltd. to Report First Half, 2024 Results on Aug 22, 2024Imeik Technology Development Co.,Ltd. announced that they will report first half, 2024 results on Aug 22, 2024New Risk • Apr 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (39% increase in shares outstanding).Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: CN¥2.45 (vs CN¥1.91 in 1Q 2023)First quarter 2024 results: EPS: CN¥2.45 (up from CN¥1.91 in 1Q 2023). Revenue: CN¥808.1m (up 28% from 1Q 2023). Net income: CN¥527.4m (up 27% from 1Q 2023). Profit margin: 65% (in line with 1Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥290, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Biotechs industry in China. Total loss to shareholders of 49% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥489 per share.お知らせ • Mar 30Imeik Technology Development Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024お知らせ • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing ChinaReported Earnings • Mar 20Full year 2023 earnings released: EPS: CN¥8.60 (vs CN¥5.84 in FY 2022)Full year 2023 results: EPS: CN¥8.60 (up from CN¥5.84 in FY 2022). Revenue: CN¥2.87b (up 48% from FY 2022). Net income: CN¥1.86b (up 47% from FY 2022). Profit margin: 65% (in line with FY 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.Buy Or Sell Opportunity • Mar 16Now 20% undervaluedOver the last 90 days, the stock has risen 22% to CN¥340. The fair value is estimated to be CN¥426, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 92% in 2 years. Earnings are forecast to grow by 86% in the next 2 years.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥321, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 45% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥410 per share.Buy Or Sell Opportunity • Jan 19Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to CN¥320. The fair value is estimated to be CN¥409, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 93% in 2 years. Earnings are forecast to grow by 87% in the next 2 years.Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥321, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 47% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥424 per share.お知らせ • Dec 29Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 20, 2024Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 20, 2024お知らせ • Sep 15Imeik Technology Development Co.,Ltd. Approves Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. at its Extraordinary General Meeting of 2023 held on 13 September 2023 approved the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: CN¥2.54 (vs CN¥1.43 in 2Q 2022)Second quarter 2023 results: EPS: CN¥2.54 (up from CN¥1.43 in 2Q 2022). Revenue: CN¥829.4m (up 83% from 2Q 2022). Net income: CN¥549.3m (up 77% from 2Q 2022). Profit margin: 66% (down from 69% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.お知らせ • Aug 26Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. announced on 25 August 2023 the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.Board Change • Jul 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Independent Director Renchao Zhang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Jun 13Imeik Technology Development Co.,Ltd. (SZSE:300896) announces an Equity Buyback for CNY 400 million worth of its shares.Imeik Technology Development Co.,Ltd. (SZSE:300896) announces a share repurchase program. Under the program, the company will repurchase up to CNY 400 million worth of its shares. The shares will be repurchased at a price not more than CNY 450 per share. The repurchased shares will be used to implement equity incentives or employee stock ownership plans. The program will be valid for a period of 12 months.業績と収益の成長予測XSEC:300896 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20283,5971,8261,4671,9901012/31/20273,1201,6061,5371,7511412/31/20262,6621,3671,1541,543113/31/20262,4231,1461,0801,243N/A12/31/20252,4531,2911,1541,324N/A9/30/20252,5151,4651,2791,465N/A6/30/20252,6681,6261,2051,432N/A3/31/20252,8811,8741,4811,723N/A12/31/20243,0261,9581,6881,927N/A9/30/20243,0752,0261,8622,023N/A6/30/20243,0672,0162,0342,128N/A3/31/20243,0471,9721,9822,064N/A12/31/20232,8691,8581,8901,954N/A9/30/20232,6201,6951,5561,710N/A6/30/20232,5131,6421,4411,609N/A3/31/20232,1381,4041,2171,381N/A1/1/20231,9391,2641,0381,194N/A9/30/20221,9141,2361,1671,220N/A6/30/20221,6991,1181,0281,066N/A3/31/20221,6191,0619991,028N/A1/1/20221,448958920943N/A9/30/20211,268858809839N/A6/30/20211,101718724748N/A3/31/2021889567571589N/A12/31/2020709440394426N/A9/30/2020627376319353N/A12/31/2019558306N/A310N/A12/31/2018321123N/A135N/A12/31/201722282N/A84N/A12/31/201614153N/A55N/A12/31/201511218N/A48N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 300896の予測収益成長率 (年間16.3% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: 300896の収益 ( 16.3% ) CN市場 ( 27.2% ) よりも低い成長が予測されています。高成長収益: 300896の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 300896の収益 ( 14.6% ) CN市場 ( 16.2% ) よりも低い成長が予測されています。高い収益成長: 300896の収益 ( 14.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 300896の 自己資本利益率 は、3年後には低くなると予測されています ( 18.7 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 06:36終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Imeik Technology Development Co.,Ltd. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Ethan CuiBofA Global ResearchPei ChengChina Galaxy Securities Co., Ltd.Zhuonan XuChina International Capital Corporation Limited21 その他のアナリストを表示
お知らせ • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2026 Results on Apr 23, 2026Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Mar 19Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 16, 2026, at 14:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China
お知らせ • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026
お知らせ • Nov 15Imeik Technology Development Co.,Ltd. Announces Directorate AppointmentsImeik Technology Development Co.,Ltd. at its EGM held on 13 November 2025 approved appointment of Jian Qing, non-independent director and Chen Zhong, non-independent director.
お知らせ • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025
お知らせ • Aug 21Imeik Technology Development Co.,Ltd. Proposes Interim Dividend for 2025Imeik Technology Development Co.,Ltd. proposed 2025 interim profit distribution plan. Cash dividend/10 shares (tax included): CNY 12.00000000, at the EGM to be held on September 11, 2025.
お知らせ • Jul 02Imeik Technology Development Co.,Ltd. to Report First Half, 2025 Results on Aug 19, 2025Imeik Technology Development Co.,Ltd. announced that they will report first half, 2025 results on Aug 19, 2025
お知らせ • Apr 22Imeik Technology Development Co.,Ltd. Approves Cash Dividend for the Year 2024Imeik Technology Development Co.,Ltd. held its Annual General Meeting of 2024 on 18 April 2025 approved the Cash dividend (tax included) of CNY 38.00000000 per 10 shares for the year 2024.
お知らせ • Mar 31Imeik Technology Development Co.,Ltd. to Report Q1, 2025 Results on Apr 25, 2025Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
お知らせ • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 18, 2025, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China
お知らせ • Dec 31Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 20, 2025Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 20, 2025
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥1.54 (vs CN¥1.51 in 3Q 2023)Third quarter 2024 results: EPS: CN¥1.54 (up from CN¥1.51 in 3Q 2023). Revenue: CN¥718.6m (up 1.1% from 3Q 2023). Net income: CN¥464.6m (up 2.1% from 3Q 2023). Profit margin: 65% (in line with 3Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to CN¥212, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥288 per share.
Buy Or Sell Opportunity • Oct 11Now 24% undervaluedOver the last 90 days, the stock has risen 25% to CN¥212. The fair value is estimated to be CN¥278, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 63% in 2 years. Earnings are forecast to grow by 58% in the next 2 years.
お知らせ • Sep 30Imeik Technology Development Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥164, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥274 per share.
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥139, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥277 per share.
Reported Earnings • Aug 22Second quarter 2024 earnings released: EPS: CN¥1.97 (vs CN¥1.82 in 2Q 2023)Second quarter 2024 results: EPS: CN¥1.97 (up from CN¥1.82 in 2Q 2023). Revenue: CN¥848.8m (up 2.3% from 2Q 2023). Net income: CN¥593.5m (up 8.0% from 2Q 2023). Profit margin: 70% (up from 66% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • Jun 29Imeik Technology Development Co.,Ltd. to Report First Half, 2024 Results on Aug 22, 2024Imeik Technology Development Co.,Ltd. announced that they will report first half, 2024 results on Aug 22, 2024
New Risk • Apr 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (39% increase in shares outstanding).
Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: CN¥2.45 (vs CN¥1.91 in 1Q 2023)First quarter 2024 results: EPS: CN¥2.45 (up from CN¥1.91 in 1Q 2023). Revenue: CN¥808.1m (up 28% from 1Q 2023). Net income: CN¥527.4m (up 27% from 1Q 2023). Profit margin: 65% (in line with 1Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥290, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Biotechs industry in China. Total loss to shareholders of 49% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥489 per share.
お知らせ • Mar 30Imeik Technology Development Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024Imeik Technology Development Co.,Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024
お知らせ • Mar 20Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024Imeik Technology Development Co.,Ltd., Annual General Meeting, Apr 17, 2024, at 15:00 China Standard Time. Location: 1F, Yard No. 20, Jinping West Road, Mafang Industrial Park, Pinggu District, Beijing China
Reported Earnings • Mar 20Full year 2023 earnings released: EPS: CN¥8.60 (vs CN¥5.84 in FY 2022)Full year 2023 results: EPS: CN¥8.60 (up from CN¥5.84 in FY 2022). Revenue: CN¥2.87b (up 48% from FY 2022). Net income: CN¥1.86b (up 47% from FY 2022). Profit margin: 65% (in line with FY 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.
Buy Or Sell Opportunity • Mar 16Now 20% undervaluedOver the last 90 days, the stock has risen 22% to CN¥340. The fair value is estimated to be CN¥426, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 92% in 2 years. Earnings are forecast to grow by 86% in the next 2 years.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥321, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 45% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥410 per share.
Buy Or Sell Opportunity • Jan 19Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to CN¥320. The fair value is estimated to be CN¥409, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has grown by 38%. Revenue is forecast to grow by 93% in 2 years. Earnings are forecast to grow by 87% in the next 2 years.
Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥321, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 47% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥424 per share.
お知らせ • Dec 29Imeik Technology Development Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 20, 2024Imeik Technology Development Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 20, 2024
お知らせ • Sep 15Imeik Technology Development Co.,Ltd. Approves Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. at its Extraordinary General Meeting of 2023 held on 13 September 2023 approved the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.
Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: CN¥2.54 (vs CN¥1.43 in 2Q 2022)Second quarter 2023 results: EPS: CN¥2.54 (up from CN¥1.43 in 2Q 2022). Revenue: CN¥829.4m (up 83% from 2Q 2022). Net income: CN¥549.3m (up 77% from 2Q 2022). Profit margin: 66% (down from 69% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China.
お知らせ • Aug 26Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023Imeik Technology Development Co.,Ltd. announced on 25 August 2023 the profit distribution proposal for the first half of 2023 as follows: Cash dividend/10 shares (tax included): CNY 18.48000000.
Board Change • Jul 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Independent Director Renchao Zhang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Jun 13Imeik Technology Development Co.,Ltd. (SZSE:300896) announces an Equity Buyback for CNY 400 million worth of its shares.Imeik Technology Development Co.,Ltd. (SZSE:300896) announces a share repurchase program. Under the program, the company will repurchase up to CNY 400 million worth of its shares. The shares will be repurchased at a price not more than CNY 450 per share. The repurchased shares will be used to implement equity incentives or employee stock ownership plans. The program will be valid for a period of 12 months.